<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077310</url>
  </required_header>
  <id_info>
    <org_study_id>0908005572</org_study_id>
    <secondary_id>1R01AA018944</secondary_id>
    <nct_id>NCT01077310</nct_id>
  </id_info>
  <brief_title>Alcohol Pharmacotherapy for HIV+ Prisoners</brief_title>
  <acronym>INSPIRE</acronym>
  <official_title>Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus
      intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual
      of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem
      drinking, who are transitioning to the community and seeking treatment to prevent relapse to
      alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved
      HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol
      treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of
      reincarceration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INSPIRE is a randomized controlled trial of injectable intramuscular NTX (XR-NTX) versus
      intramuscular placebo among Human Immunodeficiency (HIV) infected prisoners meeting DSM-IV
      criteria for alcohol dependence or problem drinking, who are transitioning to the community
      and seeking treatment to prevent relapse to alcohol use. While the COMBINE trial has
      demonstrated the effectiveness of oral naltrexone in a group of active alcohol dependent
      persons in decreasing relapse to alcohol use over placebo, naltrexone has not been studied in
      people who have a history of current alcohol dependence prior to incarceration, are
      incarcerated and not actively using alcohol and are likely to return to alcohol use when
      released. In this study, we conduct a placebo-controlled trial to determine if naltrexone has
      an effect in this group, which could be important in making the case for having naltrexone
      available to alcohol dependent or problem drinking HIV+ prisoners prior to release. We will
      compare their HIV treatment (HIV-1 RNA levels, CD4 count), alcohol treatment (time to relapse
      to heavy drinking, percent of days drinking, percent of days abstinent and alcohol craving)
      and HIV risk behavior (sexual and drug-related risks) outcomes. The hypotheses include:

      i. XR-NTX will result in improved HIV clinical outcomes, including changes in HIV-1 RNA
      levels, and higher CD4 counts.

      ii. XR-NTX will result in improved alcohol treatment outcomes, including longer time to
      alcohol relapse, lower percent days drinking, and lower craving for alcohol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Those Maintain or Improve to HIV RNA-1 Viral Load Less Then 400 Copies/mL</measure>
    <time_frame>Baseline to month 6 post release</time_frame>
    <description>Percentage of participants that maintained or improved a level of undetectable HIV viral load from baseline (closest viral load to time of release from incarceration) to 6 months post release. Missing lab values were considered to have a detectable HIV viral load.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol Treatment Outcome: Time to Alcohol Relapse</measure>
    <time_frame>Post release</time_frame>
    <description>Self reported time to first heavy drinking day after release from incarceration, up to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Treatment Outcome: Change in Average Drinks Per Drinking Day</measure>
    <time_frame>12 weeks prior to release from prison (baseline) to 6 months post release</time_frame>
    <description>The mean change from 12 weeks pre incarceration to 6 months post release from incarceration in average drinks per drinking day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Treatment Outcome: Change in Percent of Heavy Drinking Days</measure>
    <time_frame>change in percent of heavy drinking days12 weeks prior to release from prison (baseline), day of release, to 6 months post-release</time_frame>
    <description>change in the percent of heavy drinking days from 12 weeks prior to incarceration to 6 months post release from incarceration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Change in CD4 Cell Count (Cells/mL)</measure>
    <time_frame>Baseline and every 3 months for 1 year</time_frame>
    <description>Baseline labs will be drawn while subjects is in prison, one to three months prior to release. Additionally, blood will be drawn every 3 months for 1 year to monitor changes in CD4 cell count.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Problem Drinking</condition>
  <condition>Hazardous Drinking</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Intramuscular naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivitrol- Intramuscular naltrexone (depot-formulation)</intervention_name>
    <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
    <arm_group_label>Intramuscular naltrexone</arm_group_label>
    <other_name>VIVITROL</other_name>
    <other_name>extended release naltrexone</other_name>
    <other_name>Intramuscular naltrexone</other_name>
    <other_name>Depot-naltrexone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV+

          2. Inmates returning to New Haven or Hartford

          3. Meets criteria for alcohol dependence (using Diagnostic and Statistical Manual IV) or
             problem drinking (using Alcohol Use Disorder Identification Test-AUDIT)

          4. Gives informed consent

          5. English or Spanish speaker

          6. &gt; 18 yrs

        Exclusion Criteria:

          1. On opiate pain medication or expressing need for them

          2. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) &gt; 5x the upper
             limit of normal

          3. Evidence of Child's Pugh Class C cirrhosis

          4. Pending felony charges

          5. Pregnant or unwilling to take contraceptive measures

          6. Subject is part of another pharmacological research study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra A Springer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick L Altice, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Clinical Research</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014 Mar;37(2):209-18. doi: 10.1016/j.cct.2013.12.006. Epub 2013 Dec 31.</citation>
    <PMID>24384538</PMID>
  </reference>
  <results_reference>
    <citation>Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. J Subst Abuse Treat. 2014 Jul;47(1):35-40. doi: 10.1016/j.jsat.2014.02.008. Epub 2014 Mar 12.</citation>
    <PMID>24674234</PMID>
  </results_reference>
  <results_reference>
    <citation>Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015 Dec 1;157:158-65. doi: 10.1016/j.drugalcdep.2015.10.023. Epub 2015 Oct 28. Erratum in: Drug Alcohol Depend. 2016 Apr 1;161:372. Altice, Frederick L [added].</citation>
    <PMID>26560326</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <results_first_submitted>August 4, 2016</results_first_submitted>
  <results_first_submitted_qc>October 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2016</results_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Alcohol dependence</keyword>
  <keyword>CD4</keyword>
  <keyword>HIV-1 RNA</keyword>
  <keyword>Alcohol treatment outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Extended-release Naltrexone</title>
          <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Extended-release Naltrexone</title>
          <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="8.1"/>
                    <measurement group_id="B2" value="45.2" spread="8.9"/>
                    <measurement group_id="B3" value="45.0" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (non Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White (non Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol use severity by AUDIT</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Abstinent or Low Risk Drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hazardous Drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Harmful Drinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible Dependence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Those Maintain or Improve to HIV RNA-1 Viral Load Less Then 400 Copies/mL</title>
        <description>Percentage of participants that maintained or improved a level of undetectable HIV viral load from baseline (closest viral load to time of release from incarceration) to 6 months post release. Missing lab values were considered to have a detectable HIV viral load.</description>
        <time_frame>Baseline to month 6 post release</time_frame>
        <population>Logistic regression backward stepwise models were used to find predictors of HIV viral suppression.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Naltrexone</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Those Maintain or Improve to HIV RNA-1 Viral Load Less Then 400 Copies/mL</title>
          <description>Percentage of participants that maintained or improved a level of undetectable HIV viral load from baseline (closest viral load to time of release from incarceration) to 6 months post release. Missing lab values were considered to have a detectable HIV viral load.</description>
          <population>Logistic regression backward stepwise models were used to find predictors of HIV viral suppression.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Treatment Outcome: Time to Alcohol Relapse</title>
        <description>Self reported time to first heavy drinking day after release from incarceration, up to 6 months</description>
        <time_frame>Post release</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended-release Naltrexone</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Treatment Outcome: Time to Alcohol Relapse</title>
          <description>Self reported time to first heavy drinking day after release from incarceration, up to 6 months</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Age 20-29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="25.8"/>
                    <measurement group_id="O2" value="9.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age 30-39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" spread="49.5"/>
                    <measurement group_id="O2" value="73.9" spread="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agge 40-49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" spread="70.4"/>
                    <measurement group_id="O2" value="85.0" spread="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age 50+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="74.1"/>
                    <measurement group_id="O2" value="64.1" spread="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Treatment Outcome: Change in Average Drinks Per Drinking Day</title>
        <description>The mean change from 12 weeks pre incarceration to 6 months post release from incarceration in average drinks per drinking day</description>
        <time_frame>12 weeks prior to release from prison (baseline) to 6 months post release</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended-release Naltrexone, Received 0-3 Injections</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Received 0-3 Injections</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
          </group>
          <group group_id="O3">
            <title>Extended-release Naltrexone, Received 4-6 Injections</title>
          </group>
          <group group_id="O4">
            <title>Placebo, Received 4-6 Injections</title>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Treatment Outcome: Change in Average Drinks Per Drinking Day</title>
          <description>The mean change from 12 weeks pre incarceration to 6 months post release from incarceration in average drinks per drinking day</description>
          <units>standard units of alcohol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="22.2"/>
                    <measurement group_id="O2" value="-29.6" spread="27.5"/>
                    <measurement group_id="O3" value="-17.4" spread="25.0"/>
                    <measurement group_id="O4" value="-14.9" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol Treatment Outcome: Change in Percent of Heavy Drinking Days</title>
        <description>change in the percent of heavy drinking days from 12 weeks prior to incarceration to 6 months post release from incarceration.</description>
        <time_frame>change in percent of heavy drinking days12 weeks prior to release from prison (baseline), day of release, to 6 months post-release</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Extended-release Naltrexone, Received 0-3 Injections</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Received 0-3 Injections</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
          </group>
          <group group_id="O3">
            <title>Extended-release Naltrexone, Received 4-6 Injections</title>
          </group>
          <group group_id="O4">
            <title>Placebo, Received 4-6 Injections</title>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Treatment Outcome: Change in Percent of Heavy Drinking Days</title>
          <description>change in the percent of heavy drinking days from 12 weeks prior to incarceration to 6 months post release from incarceration.</description>
          <units>percent of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.3" spread="44.8"/>
                    <measurement group_id="O2" value="-51.3" spread="41.1"/>
                    <measurement group_id="O3" value="-63.6" spread="38.8"/>
                    <measurement group_id="O4" value="-54.9" spread="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Change in CD4 Cell Count (Cells/mL)</title>
        <description>Baseline labs will be drawn while subjects is in prison, one to three months prior to release. Additionally, blood will be drawn every 3 months for 1 year to monitor changes in CD4 cell count.</description>
        <time_frame>Baseline and every 3 months for 1 year</time_frame>
        <population>These data were not able to be collected for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Extended-release Naltrexone, Received 0-3 Injections</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Received 0-3 Injections</title>
            <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
          </group>
          <group group_id="O3">
            <title>Extended-release Naltrexone, Received 4-6 Injections</title>
          </group>
          <group group_id="O4">
            <title>Placebo, Received 4-6 Injections</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in CD4 Cell Count (Cells/mL)</title>
          <description>Baseline labs will be drawn while subjects is in prison, one to three months prior to release. Additionally, blood will be drawn every 3 months for 1 year to monitor changes in CD4 cell count.</description>
          <population>These data were not able to be collected for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>full study duration, up to 48 weeks post release</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Extended-release Naltrexone</title>
          <description>Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
Vivitrol- Intramuscular naltrexone (depot-formulation): Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
Placebo: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>known medication side affect</description>
                <counts group_id="E1" events="22" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>known drug side effect</description>
                <counts group_id="E1" events="14" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principle Investigator</name_or_title>
      <organization>Yale School of Medicine</organization>
      <phone>203-737-2883</phone>
      <email>sandra.springer@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

